Get the latest on Moderna’s Q3 earnings, analyst forecasts, COVID-19 vaccine sales impact, and what could shape MRNA’s stock ...

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Impatient investors dumped shares of COVID-19 vaccine maker Moderna (MRNA) on Monday. On Oct 30, the firm canceled a UBS ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...

An AI collaboration boosted the company behind the largest U.S. cloud service on Monday, Nov. 3, 2025, while shares of the ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

The stock has surged roughly 157% YTD, yet both Wall Street and Seeking Alpha’s Quant Rating keep a Hold due to valuation concerns. Piper Sandler lifted its price target to $210 from $182 while ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee ...